Short Communication: Bioequivalence of Tenofovir Component of Tenofovir/Rilpivi

Peter R. Chai, Luis M. Pereira, Guruprasad D. Jambaulikar, Adam Carrico, Conall O'Cleirigh, Kenneth H. Mayer, Edward W. Boyer

Research output: Contribution to journalArticle

Abstract

Digital pills, gelatin capsules with radiofrequency transmitters activated by stomach chloride ions, directly measure antiretroviral therapy adherence. In individuals with substance use disorders and HIV, real-time nonadherence detected by digital pills creates a platform to deliver substance use and adherence interventions. In this study, we determined the bioequivalence of tenofovir (TFV), administered as tenofovir disoproxil fumarate (TDF) in healthy human volunteers administered a commercial drug product and a digital pill formulation. We adhered generally to the US FDA Analytical Procedures and Methods for Validation for Drugs and Biologics guidelines. Ten HIV-uninfected adults without reported allergy to TFV, emtricitabine, or rilpivirine were enrolled. Participants ingested a digital pill containing TDF/emtricitabine/rilpivirine. Peripheral venous blood samples were collected at 0.5, 1, 2, 4, 8, and 24 h postingestion. After a 14-day washout period, the same participants ingested Complera™. Serial venous blood samples were collected using the same protocol as the digital pill. Liquid chromatography/mass spectrometry was used to determine a maximum concentration (Cmax), area under curve from time zero to last measured concentration (AUCo-t), and area under curve from time zero to infinity (AUCoo) of TFV. Ten participants with an average age of 27 and body mass index of 25.4 successfully completed the study. Predose TFV was undetectable before the second administration of Complera confirming adequate washout period after ingestion of the digital pill. The geometric means of AUCo-t, AUCoo, and Cmax for test and reference products were within the 95% confidence intervals and, therefore, bioequivalent. TFV overencapsulated in digital pills are bioequivalent to TFV in commercial formulations.

Original languageEnglish (US)
Pages (from-to)361-363
Number of pages3
JournalAIDS research and human retroviruses
Volume35
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Tenofovir
Therapeutic Equivalency
Communication
Rilpivirine
Area Under Curve
HIV
Gelatin
Biological Products
Liquid Chromatography
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Chai, P. R., Pereira, L. M., Jambaulikar, G. D., Carrico, A., O'Cleirigh, C., Mayer, K. H., & Boyer, E. W. (2019). Short Communication: Bioequivalence of Tenofovir Component of Tenofovir/Rilpivi. AIDS research and human retroviruses, 35(4), 361-363. https://doi.org/10.1089/aid.2018.0073

Short Communication : Bioequivalence of Tenofovir Component of Tenofovir/Rilpivi. / Chai, Peter R.; Pereira, Luis M.; Jambaulikar, Guruprasad D.; Carrico, Adam; O'Cleirigh, Conall; Mayer, Kenneth H.; Boyer, Edward W.

In: AIDS research and human retroviruses, Vol. 35, No. 4, 01.04.2019, p. 361-363.

Research output: Contribution to journalArticle

Chai, PR, Pereira, LM, Jambaulikar, GD, Carrico, A, O'Cleirigh, C, Mayer, KH & Boyer, EW 2019, 'Short Communication: Bioequivalence of Tenofovir Component of Tenofovir/Rilpivi', AIDS research and human retroviruses, vol. 35, no. 4, pp. 361-363. https://doi.org/10.1089/aid.2018.0073
Chai, Peter R. ; Pereira, Luis M. ; Jambaulikar, Guruprasad D. ; Carrico, Adam ; O'Cleirigh, Conall ; Mayer, Kenneth H. ; Boyer, Edward W. / Short Communication : Bioequivalence of Tenofovir Component of Tenofovir/Rilpivi. In: AIDS research and human retroviruses. 2019 ; Vol. 35, No. 4. pp. 361-363.
@article{c3c7f4aed6aa4d6ab105129dd665a24d,
title = "Short Communication: Bioequivalence of Tenofovir Component of Tenofovir/Rilpivi",
abstract = "Digital pills, gelatin capsules with radiofrequency transmitters activated by stomach chloride ions, directly measure antiretroviral therapy adherence. In individuals with substance use disorders and HIV, real-time nonadherence detected by digital pills creates a platform to deliver substance use and adherence interventions. In this study, we determined the bioequivalence of tenofovir (TFV), administered as tenofovir disoproxil fumarate (TDF) in healthy human volunteers administered a commercial drug product and a digital pill formulation. We adhered generally to the US FDA Analytical Procedures and Methods for Validation for Drugs and Biologics guidelines. Ten HIV-uninfected adults without reported allergy to TFV, emtricitabine, or rilpivirine were enrolled. Participants ingested a digital pill containing TDF/emtricitabine/rilpivirine. Peripheral venous blood samples were collected at 0.5, 1, 2, 4, 8, and 24 h postingestion. After a 14-day washout period, the same participants ingested Complera™. Serial venous blood samples were collected using the same protocol as the digital pill. Liquid chromatography/mass spectrometry was used to determine a maximum concentration (Cmax), area under curve from time zero to last measured concentration (AUCo-t), and area under curve from time zero to infinity (AUCoo) of TFV. Ten participants with an average age of 27 and body mass index of 25.4 successfully completed the study. Predose TFV was undetectable before the second administration of Complera confirming adequate washout period after ingestion of the digital pill. The geometric means of AUCo-t, AUCoo, and Cmax for test and reference products were within the 95{\%} confidence intervals and, therefore, bioequivalent. TFV overencapsulated in digital pills are bioequivalent to TFV in commercial formulations.",
author = "Chai, {Peter R.} and Pereira, {Luis M.} and Jambaulikar, {Guruprasad D.} and Adam Carrico and Conall O'Cleirigh and Mayer, {Kenneth H.} and Boyer, {Edward W.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1089/aid.2018.0073",
language = "English (US)",
volume = "35",
pages = "361--363",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Short Communication

T2 - Bioequivalence of Tenofovir Component of Tenofovir/Rilpivi

AU - Chai, Peter R.

AU - Pereira, Luis M.

AU - Jambaulikar, Guruprasad D.

AU - Carrico, Adam

AU - O'Cleirigh, Conall

AU - Mayer, Kenneth H.

AU - Boyer, Edward W.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Digital pills, gelatin capsules with radiofrequency transmitters activated by stomach chloride ions, directly measure antiretroviral therapy adherence. In individuals with substance use disorders and HIV, real-time nonadherence detected by digital pills creates a platform to deliver substance use and adherence interventions. In this study, we determined the bioequivalence of tenofovir (TFV), administered as tenofovir disoproxil fumarate (TDF) in healthy human volunteers administered a commercial drug product and a digital pill formulation. We adhered generally to the US FDA Analytical Procedures and Methods for Validation for Drugs and Biologics guidelines. Ten HIV-uninfected adults without reported allergy to TFV, emtricitabine, or rilpivirine were enrolled. Participants ingested a digital pill containing TDF/emtricitabine/rilpivirine. Peripheral venous blood samples were collected at 0.5, 1, 2, 4, 8, and 24 h postingestion. After a 14-day washout period, the same participants ingested Complera™. Serial venous blood samples were collected using the same protocol as the digital pill. Liquid chromatography/mass spectrometry was used to determine a maximum concentration (Cmax), area under curve from time zero to last measured concentration (AUCo-t), and area under curve from time zero to infinity (AUCoo) of TFV. Ten participants with an average age of 27 and body mass index of 25.4 successfully completed the study. Predose TFV was undetectable before the second administration of Complera confirming adequate washout period after ingestion of the digital pill. The geometric means of AUCo-t, AUCoo, and Cmax for test and reference products were within the 95% confidence intervals and, therefore, bioequivalent. TFV overencapsulated in digital pills are bioequivalent to TFV in commercial formulations.

AB - Digital pills, gelatin capsules with radiofrequency transmitters activated by stomach chloride ions, directly measure antiretroviral therapy adherence. In individuals with substance use disorders and HIV, real-time nonadherence detected by digital pills creates a platform to deliver substance use and adherence interventions. In this study, we determined the bioequivalence of tenofovir (TFV), administered as tenofovir disoproxil fumarate (TDF) in healthy human volunteers administered a commercial drug product and a digital pill formulation. We adhered generally to the US FDA Analytical Procedures and Methods for Validation for Drugs and Biologics guidelines. Ten HIV-uninfected adults without reported allergy to TFV, emtricitabine, or rilpivirine were enrolled. Participants ingested a digital pill containing TDF/emtricitabine/rilpivirine. Peripheral venous blood samples were collected at 0.5, 1, 2, 4, 8, and 24 h postingestion. After a 14-day washout period, the same participants ingested Complera™. Serial venous blood samples were collected using the same protocol as the digital pill. Liquid chromatography/mass spectrometry was used to determine a maximum concentration (Cmax), area under curve from time zero to last measured concentration (AUCo-t), and area under curve from time zero to infinity (AUCoo) of TFV. Ten participants with an average age of 27 and body mass index of 25.4 successfully completed the study. Predose TFV was undetectable before the second administration of Complera confirming adequate washout period after ingestion of the digital pill. The geometric means of AUCo-t, AUCoo, and Cmax for test and reference products were within the 95% confidence intervals and, therefore, bioequivalent. TFV overencapsulated in digital pills are bioequivalent to TFV in commercial formulations.

UR - http://www.scopus.com/inward/record.url?scp=85063784387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063784387&partnerID=8YFLogxK

U2 - 10.1089/aid.2018.0073

DO - 10.1089/aid.2018.0073

M3 - Article

C2 - 30693811

AN - SCOPUS:85063784387

VL - 35

SP - 361

EP - 363

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 4

ER -